<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
  xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://www.tuobenessere.it/sanita-al-via-seconda-fase-corso-fad-per-aiutare-i-medici-a-lavorare-con-la-telemedicina/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-04T15:37:03+02:00</news:publication_date>
      <news:title>Sanità, al via seconda fase corso Fad per aiutare i medici a lavorare con la telemedicina</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/esperti-fossc-ai-puo-ridurre-del-25-i-costi-e-del-40-i-tempi-sviluppo-di-un-farmaco/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-04T13:05:40+02:00</news:publication_date>
      <news:title>Esperti Fossc: &quot;Ai può ridurre del 25% i costi e del 40% i tempi sviluppo di un farmaco&quot;</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/non-romperle-parte-il-tour-nelle-piazze-italiane-per-il-benessere-di-ossa-e-muscoli/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-04T12:59:13+02:00</news:publication_date>
      <news:title>&#039;Non Romperle!&#039;, parte il tour nelle piazze italiane per il benessere di ossa e muscoli</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/tumore-gastroesofageo-her2-risultati-positivi-per-tislelizumab-con-zanidatamab-e-chemio/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-04T12:50:45+02:00</news:publication_date>
      <news:title>Tumore gastroesofageo Her2+, risultati positivi per tislelizumab con zanidatamab e chemio</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/cardiomiopatia-amiloide-da-transtiretina-con-acoramidis-41-rischio-peggioramento-scompenso/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-04T12:40:22+02:00</news:publication_date>
      <news:title>Cardiomiopatia amiloide da transtiretina, con acoramidis -41% rischio peggioramento scompenso</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/fusco-ieo-ia-e-digital-pathology-con-test-genomici-per-cura-mirata-cancro-seno/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-04T10:49:00+02:00</news:publication_date>
      <news:title>Fusco (Ieo): &quot;Ia e digital pathology con test genomici per cura mirata cancro seno&quot;</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/fabi-aiom-nel-2026-uso-test-genomici-in-cancro-al-seno-atteso-al-90-in-italia/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-04T10:47:00+02:00</news:publication_date>
      <news:title>Fabi (Aiom): &quot;Nel 2026 uso test genomici in cancro al seno atteso al 90% in Italia&quot;</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/curigliano-esmo-germania-esempio-per-aderenza-a-test-genomici-cancro-al-seno/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-04T10:46:00+02:00</news:publication_date>
      <news:title>Curigliano (Esmo): &quot;Germania esempio per aderenza a test genomici cancro al seno&quot;</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/lindustria-farmaceutica-scommette-sulle-competenze-il-9-giugno-il-talk-adnkronos/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-04T07:24:00+02:00</news:publication_date>
      <news:title>L’industria farmaceutica scommette sulle competenze, il 9 giugno il talk Adnkronos</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/miele-da-sballo-allarme-tra-giovani-primo-passo-verso-altre-sostanze-pericolo-e-il-crack/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-04T00:12:06+02:00</news:publication_date>
      <news:title>&#039;Miele da sballo&#039;, allarme tra giovani: &quot;Primo passo verso altre sostanze, pericolo è il crack&quot;</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/mappato-il-microbioma-di-otzi-luomo-dei-ghiacci-la-scoperta-super-lieviti-resistenti-al-freddo-primo-test-il-pane/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-03T17:41:34+02:00</news:publication_date>
      <news:title>Mappato il microbioma di Ötzi l&#039;uomo dei ghiacci. La scoperta: super lieviti resistenti al freddo, primo test il pane</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/ebola-60-morti-su-344-casi-in-congo-oms-ci-si-puo-salvare-8-sono-i-guariti/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-03T16:34:43+02:00</news:publication_date>
      <news:title>Ebola, 60 morti su 344 casi in Congo. Oms: &quot;Ci si può salvare, 8 sono i guariti&quot;</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/cose-il-miele-da-sballo-lesperta-thc-fino-al-90-puo-causare-psicosi-e-coma/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-03T13:50:24+02:00</news:publication_date>
      <news:title>Cos&#039;è il &#039;miele da sballo&#039;, l&#039;esperta: &quot;Thc fino al 90%, può causare psicosi e coma&quot;</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/nella-farmacia-dei-servizi-da-screening-a-test-diagnostici-fino-al-supporto-ai-pazienti-cronici-arriva-il-manuale-certificato-dagli-ordini/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-03T13:31:25+02:00</news:publication_date>
      <news:title>Nella farmacia dei servizi da screening a test diagnostici fino al supporto ai pazienti cronici, arriva il Manuale certificato dagli Ordini</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/cancro-prostata-avanzato-studio-asco-conferma-vantaggio-cognitivo-di-darolutamide/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-03T12:54:25+02:00</news:publication_date>
      <news:title>Cancro prostata avanzato, studio Asco conferma vantaggio cognitivo di darolutamide</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/leucemia-mieloide-cronica-asciminib-conferma-efficacia-e-sicurezza-a-3-anni/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-03T12:42:12+02:00</news:publication_date>
      <news:title>Leucemia mieloide cronica, asciminib conferma efficacia e sicurezza a 3 anni</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/cancro-polmone-ok-ue-a-lurbinectedina-piu-atezolizumab-in-prima-linea/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-03T12:25:22+02:00</news:publication_date>
      <news:title>Cancro polmone, ok Ue a lurbinectedina più atezolizumab in prima linea</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/malattia-di-chagas-spaventa-lamerica-latina-circa-6-mln-convivono-con-linfezione-parassitaria/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-03T11:42:00+02:00</news:publication_date>
      <news:title>Malattia di Chagas spaventa l&#039;America Latina, circa 6 mln convivono con l&#039;infezione parassitaria</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.tuobenessere.it/farmacie-online-lapproccio-innovativo-di-meafarma-che-ridefinisce-lesperienza-utente/</loc>
    <news:news>
      <news:publication>
        <news:name>Tuo Benessere</news:name>
        <news:language>it</news:language>
      </news:publication>
      <news:publication_date>2026-06-03T11:21:44+02:00</news:publication_date>
      <news:title>Farmacie online: l&#039;approccio innovativo di Meafarma che ridefinisce l’esperienza utente</news:title>
    </news:news>
  </url>
</urlset>
<!-- Generated: 2026-06-04 16:27:23 | Posts: 19 -->
